Giaccone G, Smit E F, van Meerbeeck J P, Splinter T, Golding R P, Pinedo H M, Laan D, van Tinteren H, Postmus P E
University Hospital Vrije Universiteit Amsterdam, The Netherlands.
Ann Oncol. 2000 Jan;11(1):109-12. doi: 10.1023/a:1008321000887.
Thirty patients with chemotherapy-naïve advanced non-small-cell lung cancer (NSCLC) were given escalating doses of paclitaxel (150, 175, 200 mg/m2) on day 1 in three consecutive cycles, together with a fixed dose of gemcitabine 1000 mg/m2 on days 1 and 8; cycles were repeated every three weeks. The dose escalation of paclitaxel was feasible in the majority of patients. Subsequently, 30 other NSCLC patients received a dose of 200 mg/m2 paclitaxel with gemcitabine 1000 mg/m2 in a phase II study. The major side effect was mild myelosuppression. A response rate of 24% was achieved in 49 fully evaluable patients. This regimen proved to be safe and easy to administer on an out-patient setting, and constitutes now one of the arms of the current EORTC randomized study for advanced NSCLC.
